Geopolitics, AI Superpowers, and the Future of Biomedical Data Access: Who Controls the Knowledge?

The geopolitics driving artificial intelligence superpowers is reshaping biomedical datasets, and who has access to them.

As nations compete for strategic advantage in AI and genomics, control over health data has become a focal point of international policy. The United States Department of Justice issued a rule effective April 8, 2025, that restricts the transfer of bulk human genomic data to countries of concern, including China, Russia, Cuba, Iran, Venezuela, and North Korea. This rule, stemming from Executive Order 14117 signed by President Joe Biden on February 28, 2024, aims to prevent access to sensitive personal data by foreign adversaries amid rising technological rivalry.

China has responded by accelerating efforts to build its own national gene bank to secure control over its biological genetic data. Experts note that while genetic-based weapons remain a distant prospect, the economic value of large-scale genomic datasets has intensified regulatory scrutiny in both countries. The U.S. Rule specifically targets bulk human genomic data and certain other ‘omics data, reflecting concerns over commercial and research transactions in the life sciences sector.

These developments are part of a broader trend in which data — particularly from digital pathology and AI-driven medical research — is increasingly treated as a strategic asset. A single histological slide can yield over two gigabytes of digital information, much of which remains underutilized due to fragmented governance and unclear data ownership. As AI systems rely on vast, diverse datasets to improve diagnostic accuracy and drug discovery, questions about who controls, accesses, and benefits from this data are gaining urgency.

International forums and alliances are being reshaped by debates over digital dominance, with trade barriers rising and nations competing to secure control over data and the digital tools of the future. In this environment, biomedical data is not only essential for advancing cancer research, metabolic disease studies, infectious disease tracking, and neuroscience but also a lever in global power dynamics.

While the full impact of these policies on global health research collaboration remains uncertain, the intersection of genomics, AI, and national security is redefining the landscape of medical innovation. Researchers and institutions now navigate a complex web of compliance requirements that vary by jurisdiction, potentially limiting the sharing of datasets critical for understanding diseases across diverse populations.

As of April 24, 2026, the conversation around health data ownership has evolved beyond privacy and consent to include questions of sovereignty, economic competitiveness, and strategic resilience. The future of biomedical progress may depend not only on scientific breakthroughs but on how nations balance open science with data security in an era of technological rivalry.